Silevertinib联合替莫唑胺治疗新诊断的未甲基化MGMT和EGFRvIII胶质母细胞瘤研究
一项2期随机、多中心研究,旨在评估口服EGFR抑制剂Silevertinib联合替莫唑胺在未甲基化MGMT启动子和EGFRvIII新诊断胶质母细胞瘤患者中的疗效和安全性
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.
Specifically, this study is being done to find answers to the following questions:
- How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM?
- What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)?
- Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?
研究概览
地位
详细说明
Silevertinib was designed to block a growth signal important to some cancers where tumors grow because of changes in a protein called epidermal growth factor receptor (EGFR). These changes are called gene amplifications, mutations, or alterations and are found in tumors. Temozolomide is a drug that fights cancer cells by damaging DNA (the genetic material of cells), which could cause the tumor cells to die. It is the standard treatment for adults with certain types of newly diagnosed brain cancer, like GBM. It is given together with radiotherapy and sometimes afterward as maintenance therapy.
This study has 2 parts. To be eligible for the study, participants must have received a diagnosis of GBM, had surgery to remove or reduce the size of the tumor, and received adjuvant radiation therapy and temozolomide. No other prior treatments for GBM are allowed.
In Part 1 (called the Safety Lead-in), participants will receive silevertinib combined with temozolomide to determine if the combination is safe and to find the best dose. Approximately 12 participants are expected to enroll in Part 1 of the study.
In Part 2, all participants will be randomized to one of two different treatment groups:
- Group 1: Silevertinib + temozolomide
- Group 2: Temozolomide only
Approximately 150 participants are expected to be randomized in Part 2 of the study.
In both Part 1 and Part 2, the study treatment will be given in "cycles". Each cycle will be 28 days. After a cycle ends, the next cycle will immediately begin the next day. Both silevertinib and temozolomide will be taken orally. Silevertinib is taken daily until disease progression and temozolomide is taken for the first 5 days of each cycle (up to 6 cycles).
If participants are found to be eligible for the study and enrolled (in Part 1) or randomized (in Part 2), participants will:
- Take the study drug as directed
- Return for frequent clinic visits to monitor overall health and status of GBM
- Undergo imaging and other laboratory tests to determine status of GBM
- Complete a paper diary at home to record the date and time(s) that the study drug is taken
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Black Diamond Therapeutics Clinical Trial Navigation Service
- 电话号码:(866) 955-4397
- 邮箱:blackdiamondtx@careboxhealth.com
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- 招聘中
- University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
-
接触:
- Staci Hankins
- 电话号码:205-644-9891
- 邮箱:sshea@uabmc.edu
-
-
Arkansas
-
Springdale、Arkansas、美国、72762
- 招聘中
- Highlands Oncology Group
-
接触:
- Renee Feast
- 电话号码:479-878-7004
- 邮箱:rfeast@hogonc.com
-
-
California
-
La Jolla、California、美国、92037-0845
- 招聘中
- UCSD Moores Cancer Center
-
接触:
- Sheila Medina
- 电话号码:(866) 955-4397
- 邮箱:s4medina@health.ucsd.edu
-
Los Angeles、California、美国、90048
- 招聘中
- Cedars-Sinai Medical Center
-
接触:
- Shannon Cyhan, RN, BSN, CCRC
- 电话号码:310-248-7855
- 邮箱:shannon.cyhan@cshs.org
-
Orange、California、美国、92868
- 招聘中
- UC Irvine Health
-
接触:
- Manisha Dandekar
- 电话号码:(866) 955-4397
- 邮箱:mdandeka@hs.uci.edu
-
Palo Alto、California、美国、94304
- 招聘中
- Stanford University
-
接触:
- Kelly Tanner
- 电话号码:650-724-5361
- 邮箱:secure-sci-cto-neuro-crcs@lists.stanford.edu
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- 招聘中
- Yale Cancer Center
-
接触:
- Amy Rodrigues
- 电话号码:203-260-9632
- 邮箱:amy.rodrigues@yale.edu
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20016
- 招聘中
- Johns Hopkins Sibley Memorial Hospital
-
接触:
- Solmaz Sahebjam, MD
- 电话号码:202-660-6500
- 邮箱:ssahebj1@jh.edu
-
-
Florida
-
Miami、Florida、美国、33176
- 招聘中
- Miami Cancer Institute
-
接触:
- Anais Vega
- 电话号码:786-527-8861
- 邮箱:Anais.Vega@baptisthealth.net
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center
-
接触:
- Carie Bliss
- 电话号码:813-745-2131
- 邮箱:Carie.Bliss@moffitt.org
-
-
Georgia
-
Atlanta、Georgia、美国、30318
- 招聘中
- Piedmont Oncology Research
-
接触:
- Jeff Whorton
- 电话号码:770-630-9299
- 邮箱:Jeff.Whorton@piedmont.org
-
-
Maine
-
Scarborough、Maine、美国、04074
- 招聘中
- Maine Health Cancer Care and Blood Disorders - Scarborough
-
接触:
- Christie Frick
- 电话号码:1 (207) 396-6369
- 邮箱:christie.frick@mainehealth.org
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 招聘中
- Johns Hopkins Sidney Kimmel Cancer Center - Baltimore
-
接触:
- Solmaz Sahebjam, MD
- 电话号码:202-660-6500
- 邮箱:ssahebj1@jh.edu
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 招聘中
- Massachusetts General Hospital
-
接触:
- Isabel Arrillaga-Romany
- 电话号码:617-724-8770
- 邮箱:iarrillaga@mgh.harvard.edu
-
Boston、Massachusetts、美国、02215
- 招聘中
- Beth Israel Deaconess Medical Center
-
接触:
- Ka-Wai Ho, MD
- 电话号码:617-667-2100
- 邮箱:Kho5@bidmc.harvard.edu
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana Farber Cancer Institute
-
接触:
- Kathryn Partridge
- 电话号码:508-340-0348
- 邮箱:Kathryn_Partridge@DFCI.HARVARD.EDU
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan
-
接触:
- Cancer Answer Line
- 电话号码:800-865-1125
- 邮箱:CancerAnswerLine@med.umich.edu
-
Detroit、Michigan、美国、48202
- 招聘中
- Henry Ford Cancer- Detroit
-
接触:
- Meghan Gauronskas, RN
- 电话号码:(866) 955-4397
- 邮箱:mgauron1@hfhs.org
-
接触:
- Nicole Beck
- 电话号码:(866) 955-4397
- 邮箱:nbeck2@hfhs.org
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- 招聘中
- Atrium Health Levine Cancer Institute
-
接触:
- Amanda Seifts
- 电话号码:980-442-2000
- 邮箱:amanda.seifts@advocatehealth.org
-
-
Missouri
-
St Louis、Missouri、美国、63108
- 招聘中
- Washington University School of Medicine Siteman Cancer Center
-
接触:
- Kelsey Etter
- 电话号码:314-273-0656
- 邮箱:etter@wustl.edu
-
-
Nebraska
-
Omaha、Nebraska、美国、68106
- 招聘中
- University of Nebraska Medical Center
-
接触:
- Michaela Savine
- 电话号码:402-836-9488
- 邮箱:misavine@unmc.edu
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- 招聘中
- John Theurer Cancer Center at Hackensack University Medical Center
-
接触:
- Oncology Clinical Research Referral Office
- 电话号码:551-996-1777
- 邮箱:OncologyResearchReferral@hmhn.org
-
New Brunswick、New Jersey、美国、08901
- 招聘中
- Rutgers Cancer Institute
-
接触:
- Xiaoru Chen
- 电话号码:(866) 955-4397
- 邮箱:xc194@cinj.rutgers.edu
-
Summit、New Jersey、美国、07901
- 招聘中
- Atlantic Health
-
接触:
- Samantha Caulfield, RN
- 电话号码:908-598-6561
- 邮箱:Samantha.caulfield@atlantichealth.org
-
-
New York
-
Lake Success、New York、美国、11042
- 招聘中
- Northwell Health Center for Advanced Medicine - Brain Tumor Center
-
接触:
- Center for Advanced Medicine - Brain Tumor Center
- 电话号码:516-253-7753
- 邮箱:neurosurgeryresearch@northwell.edu
-
New York、New York、美国、10032
- 招聘中
- Columbia University Irving Medical Center
-
接触:
- Research Nurse Navigator
- 电话号码:212-342-5162
- 邮箱:Cancerclinicaltrials@cumc.columbia.edu
-
The Bronx、New York、美国、10461
- 招聘中
- Montefiore Medical Center
-
接触:
- Yoko Eng
- 电话号码:718-405-8516
- 邮箱:yeng@montefiore.org
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- 招聘中
- Atrium Health Levine Cancer Institute
-
接触:
- Amanda Seifts
- 电话号码:980-442-2000
- 邮箱:amanda.seifts@advocatehealth.org
-
Winston-Salem、North Carolina、美国、27157
- 招聘中
- Atrium Health Wake Forest Baptist
-
接触:
- James Morgan
- 电话号码:336-702-4491
- 邮箱:James.Morgan@Advocatehealth.org
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic Taussig Cancer Center
-
接触:
- Rachel Hufsey
- 电话号码:216-442-6671
- 邮箱:HUFSEYR@ccf.org
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University
-
接触:
- Jake Lanning
- 电话号码:614-685-2435
- 邮箱:Jake.Lanning@osumc.edu
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19107
- 招聘中
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
-
接触:
- Community Research Operations & Enrollment
- 电话号码:215-600-9151
- 邮箱:ONCTrialNow@jefferson.edu
-
Pittsburgh、Pennsylvania、美国、15232
- 招聘中
- UPMC Hillman Cancer Center
-
接触:
- Linda Elias
- 电话号码:412-623-6037
- 邮箱:eliaslj@upmc.edu
-
-
South Carolina
-
Greenville、South Carolina、美国、29605
- 招聘中
- Prisma Health
-
接触:
- Kim Williams
- 电话号码:864-522-431
- 邮箱:Kim.Williams3@Prismahealth.org
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- UT MD Anderson Cancer Center
-
接触:
- Mohammed Nassfi
- 电话号码:(866) 955-4397
- 邮箱:mnassif@mdanderson.org
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- 招聘中
- Huntsman Cancer Institute, University of Utah
-
接触:
- Rachel Kingsford
- 电话号码:801-585-0115
- 邮箱:rachel.kingsford@hci.utah.edu
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- Inova Schar Cancer Institute
-
接触:
- Stephanie Van Bebber
- 电话号码:571-472-4724
- 邮箱:Stephanie.VanBebber@inova.org
-
Richmond、Virginia、美国、23298
- 招聘中
- VCU Massey Comprehensive Cancer Center
-
接触:
- Keara Mackey
- 电话号码:804-628-1894
- 邮箱:mackeyka@vcu.edu
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- 招聘中
- University of Wisconsin Carbone Cancer Center
-
接触:
- UW Cancer Connect
- 电话号码:(866) 955-4397
- 邮箱:cancerconnect@uwhealth.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Newly diagnosed histologically confirmed glioblastoma that is isocitrate dehydrogenase wild type (IDH-WT).
- Positive EGFR status in the brain tumor as determined by a commercially available test or validated laboratory assay (CLIA or comparable certification).
- For Part 1 (Safety Lead-in) ONLY: EGFR alterations.
- For Part 2 (Randomized, Controlled Trial) ONLY: EGFRvIII.
- For Part 2 (Randomized, Controlled Trial) ONLY: Unmethylated MGMT promoter tumor status based on a validated assay.
- No treatment for newly diagnosed GBM other than surgery followed by standard-of-care adjuvant postoperative radiation (54 to 60 Gy) and TMZ chemotherapy.
- At least 4 weeks since completion of radiation therapy, with a post-radiation MRI showing no progression.
Key Exclusion Criteria:
- Recurrent multifocal disease, metastatic, leptomeningeal, or extracranial GBM, or gliomatosis cerebri.
- Progression of GBM prior to Enrollment, Screening, or Randomization.
- Biopsy-only/no resectional surgery.
- Prior or concomitant treatment for GBM with an EGFR-targeting agent, including silevertinib, bevacizumab, cytotoxic chemotherapy, immunotherapy, experimental therapies, Gliadel wafers, GammaTile®, or other intratumoral or intracavitary antineoplastic therapy.
- Intent to use Optune® (TTF).
- Significant other uncontrolled health conditions or other malignancies.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:silevertinib and temozolomide
silevertinib at dose determined in Part 1 until disease progression in combination with temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles |
Participants enrolled into Part 1 (Safety Lead-In) or randomized to Arm A in Part 2 will receive silevertinib at dose determined in Part 1 until disease progression in combination with temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles.
其他名称:
|
|
有源比较器:temozolomide
temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles |
Participants randomized to Arm B will receive temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR)
大体时间:12 months
|
Progression-free survival, defined as the time from the date of randomization to the date of first disease progression per RANO 2.0 by BICR assessment or death from any cause, whichever occurs first. |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival
大体时间:18 months
|
Overall survival defined as time from first dose of study drug to death from any cause. |
18 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- BDTX-1535-201
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.